CYTK logo

Cytokinetics Incorporated (CYTK)

$72.72

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CYTK

Market cap

$10.11B

EPS

-7.23

P/E ratio

--

Price to sales

149.4

Dividend yield

--

Beta

0.360331

Price on CYTK

Previous close

$73.95

Today's open

$73.04

Day's range

$72.26 - $74.01

52 week range

$47.22 - $88.31

Profile about CYTK

CEO

Robert I. Blum

Employees

673

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

139023418

Issue type

Common Stock

CYTK industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CYTK

Cytokinetics to Participate in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi 2026 BioPharma Back to School Conference: Fireside chat on Wednesday, September 9, 2026 at 3:00 PM Eastern Time in New York, NY.

news source

GlobeNewsWire • Sep 2, 2026

news preview

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.

news source

Zacks Investment Research • Sep 2, 2026

news preview

Cytokinetics Investors Weigh Safety Data From Pivotal Trial

Cytokinetics Incorporated (NASDAQ:CYTK) on Friday shared primary results from the ACACIA-HCM Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

news source

Benzinga • Aug 31, 2026

news preview

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Additional Results from ACACIA-HCM Demonstrate Improvements in  Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM ( M etoprolol vs A ficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Late Breaking Clinical Session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany and simultaneously published in Circulation and the Journal of the American College of Cardiology: Heart Failure, respectively.

news source

GlobeNewsWire • Aug 29, 2026

news preview

Cytokinetics eyes expanded use of heart drug after promising late-stage data

Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart ​condition that currently has no approved treatments.

news source

Reuters • Aug 28, 2026

news preview

Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers

Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday.

news source

Investors Business Daily • Aug 28, 2026

news preview

Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise capacity.

news source

MarketBeat • Aug 28, 2026

news preview

Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript

Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript

news source

Seeking Alpha • Aug 28, 2026

news preview

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and simultaneously published in  The New England Journal of Medicine .1 ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to Week 36 compared to placebo in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2).

news source

GlobeNewsWire • Aug 28, 2026

news preview

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in the insider's total equity holdings.

news source

The Motley Fool • Aug 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Cytokinetics Incorporated

Open an M1 investment account to buy and sell Cytokinetics Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CYTK on M1